Neovascularization induced by hypoxia inducible transcription factor is associated with the improvement of cardiac dysfunction in experimental autoimmune myocarditis

Expert Opinion on Investigational Drugs

Volumn 23, Issue 2, 2014, Pages 149-162

  Tada, Yuko ^a   Ogawa, Masahito ^b   Watanabe, Ryo ^b   Zempo, Hirofumi ^b   Takamura, Chisato ^b   Suzuki, Jun Ichi ^c   Dan, Takashi ^d   Miyata, Toshio ^d   Isobe, Mitsuaki ^b   Komuro, Issei ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Autoimmune myocarditis; HIF; PHD

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; MYOSIN HEAVY CHAIN ALPHA; TM 6008;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE MYOCARDITIS; BLOOD VESSEL; CONTROLLED STUDY; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MYOCARDITIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN;

ANIMALS; AUTOIMMUNE DISEASES; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; MYOSIN HEAVY CHAINS; NEOVASCULARIZATION, PHYSIOLOGIC; PROLYL-HYDROXYLASE INHIBITORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84892380827     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.855196     Document Type: Article

References (67)

1. Kühl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "Idiopathic" Left ventricular dysfunction. Circulation 2005;111:887-93 (Pubitemid 40279890)
2. Kühl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005;112:1965-70 (Pubitemid 41377415)
3. Bowles NE, Ni J, Kearney DL, et al. Detection of viruses in myocardial tissues by polymerase chain reaction. Evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003;42:466-72 (Pubitemid 36951713)
4. Cooper LT. Myocarditis. N Engl J Med 2009;360:1526-38
5. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J 2008;29:2073-82
6. Cihakova D, Rose NR. Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol 2008;99:95-114
7. Neu N, Beisel KW, Traystman MD, et al. Autoantibodies specific for the cardiac myosin isoform are found in mice susceptible to coxsackievirus b3-induced myocarditis. J Immunol 1987;138:2488-92 (Pubitemid 17051821)
8. Afanasyeva M, Georgakopoulos D, Rose NR. Autoimmune myocarditis: cellular mediators of cardiac dysfunction. Autoimmun Rev 2004;3:476-86 (Pubitemid 39531238)
9. Smith SC, Allen PM. Neutralization of endogenous tumor necrosis factor ameliorates the severity of myosininduced myocarditis. Circ Res 1992;70:856-63
10. Li YC, Ge LS, Yang PL, et al. Carvedilol treatment ameliorates acute coxsackievirus b3-induced myocarditis associated with oxidative stress reduction. Eur J Pharmacol 2010;640:112-16
11. Sukumaran V, Watanabe K, Veeraveedu PT, et al. Telmisartan ameliorates experimental autoimmune myocarditis associated with inhibition of inflammation and oxidative stress. Eur J Pharmacol 2011;652:126-35
12. Loinard C, Ginouvès A, Vilar J, et al. Inhibition of prolyl hydroxylase domain proteins promotes therapeutic revascularization. Circulation 2009;120:50-9
13. Sano M, Minamino T, Toko H, et al. P53-induced inhibition of hif-1 causes cardiac dysfunction during pressure overload. Nature 2007;446:444-8 (Pubitemid 46474597)
14. Lee SH, Wolf PL, Escudero R, et al. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 2000;342:626-33 (Pubitemid 30118415)
15. Martin C, Yu AY, Jiang BH, et al. Cardiac hypertrophy in chronically anemic fetal sheep: increased vascularization is associated with increased myocardial expression of vascular endothelial growth factor and hypoxia-inducible factor 1. Am J Obstet Gynecol 1998;178:527-34 (Pubitemid 28207505)
16. Bateman RM, Tokunaga C, Kareco T, et al. Myocardial hypoxia-inducible hif-1alpha, vegf, and glut1 gene expression is associated with microvascular and icam-1 heterogeneity during endotoxemia. Am J Physiol Heart Circ Physiol 2007;293:H448-56
17. Ke Q, Costa M. Hypoxia-inducible factor-1 (hif-1). Mol Pharmacol 2006;70:1469-80
18. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify hif. Science 2001;294:1337-40 (Pubitemid 33063099)
19. Masson N, Ratcliffe PJ. Hif prolyl and asparaginyl hydroxylases in the biological response to intracellular o(2) levels. J Cell Sci 2003;116:3041-9 (Pubitemid 37038953)
20. Jaakkola P, Mole DR, Tian YM, et al. Targeting of hif-alpha to the von hippellindau ubiquitylation complex by o2-regulated prolyl hydroxylation. Science 2001;292:468-72 (Pubitemid 32335942)
21. Ivan M, Kaelin WG. The von hippellindau tumor suppressor protein. Curr Opin Genet Dev 2001;11:27-34 (Pubitemid 32119274)
22. Kallio PJ, Okamoto K, O'Brien S, et al. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the cbp/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J 1998;17:6573-86 (Pubitemid 28521792)
23. Natarajan R, Salloum FN, Fisher BJ, et al. Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. Am J Physiol Heart Circ Physiol 2007;293:H1571-80 (Pubitemid 47367202)
24. Bao W, Qin P, Needle S, et al. Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. J Cardiovasc Pharmacol 2010;56:147-55
25. Nangaku M, Izuhara Y, Takizawa S, et al. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol 2007;27:2548-54 (Pubitemid 350158904)
26. Takeda K, Cowan A, Fong GH. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 2007;116:774-81 (Pubitemid 47255995)
27. Moslehi J, Minamishima YA, Shi J, et al. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation 2010;122:1004-16
28. Zolk O, Solbach TF, Eschenhagen T, et al. Activation of negative regulators of the hypoxia-inducible factor (hif) pathway in human end-stage heart failure. Biochem Biophys Res Commun 2008;376:315-20
29. Lieb ME, Menzies K, Moschella MC, et al. Mammalian egln genes have distinct patterns of mrna expression and regulation. Biochem Cell Biol 2002;80:421-6 (Pubitemid 35365999)
30. Takeda K, Aguila HL, Parikh NS, et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 2008;111:3229-35
31. Banai S, Shweiki D, Pinson A, et al. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res 1994;28:1176-9 (Pubitemid 24264723)
32. Li J, Brown LF, Hibberd MG, et al. Vegf, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 1996;270:H1803-11
33. Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994;152:4149-56 (Pubitemid 24111088)
34. Fava RA, Olsen NJ, Spencer-Green G, et al. Vascular permeability factor/endothelial growth factor (vpf/vegf): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341-6 (Pubitemid 24181082)
35. Liu Y, Cox SR, Morita T, et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ Res 1995;77:638-43
36. Larsen H, Muz B, Khong TL, et al. Differential effects of th1 versus th2 cytokines in combination with hypoxia on hifs and angiogenesis in ra. Arthritis Res Ther 2012;14:R180
37. Sone H, Kawakami Y, Sakauchi M, et al. Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. Biochem Biophys Res Commun 2001;281:562-8 (Pubitemid 32928191)
38. Lu J, Kasama T, Kobayashi K, et al. Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. J Immunol 2000;164:5922-7 (Pubitemid 30389839)
39. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011;364:656-65
40. Katavetin P, Miyata T, Inagi R, et al. High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxiainducible factor/hypoxia-responsible element pathway. J Am Soc Nephrol 2006;17:1405-13 (Pubitemid 43673421)
41. Rosenberger C, Khamaisi M, Abassi Z, et al. Adaptation to hypoxia in the diabetic rat kidney. Kidney Int 2008;73:34-42 (Pubitemid 350273633)
42. Ema M, Taya S, Yokotani N, et al. A novel bhlh-pas factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the vegf expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997;94:4273-8
43. Tian H, McKnight SL, Russell DW. Endothelial pas domain protein 1 (epas1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997;11:72-82 (Pubitemid 27043825)
44. Skuli N, Majmundar AJ, Krock BL, et al. Endothelial hif-2alpha regulates murine pathological angiogenesis and revascularization processes. J Clin Invest 2012;122:1427-43
45. Fraisl P, Mazzone M, Schmidt T, et al. Regulation of angiogenesis by oxygen and metabolism. Dev Cell 2009;16:167-79
46. Jürgensen JS, Rosenberger C, Wiesener MS, et al. Persistent induction of hif-1alpha and-2alpha in cardiomyocytes and stromal cells of ischemic myocardium. FASEB J 2004;18:1415-17 (Pubitemid 39561599)
47. Fong GH. Mechanisms of adaptive angiogenesis to tissue hypoxia. Angiogenesis 2008;11:121-40
48. Cummins EP, Berra E, Comerford KM, et al. Prolyl hydroxylase-1 negatively regulates ikappab kinase-beta, giving insight into hypoxia-induced nfkappab activity. Proc Natl Acad Sci USA 2006;103:18154-9 (Pubitemid 44871628)
49. Winning S, Splettstoesser F, Fandrey J, et al. Acute hypoxia induces hifindependent monocyte adhesion to endothelial cells through increased intercellular adhesion molecule-1 expression: the role of hypoxic inhibition of prolyl hydroxylase activity for the induction of nf-kappa b. J Immunol 2010;185:1786-93
50. Spirig R, Djafarzadeh S, Regueira T, et al. Effects of tlr agonists on the hypoxia-regulated transcription factor hif-1alpha and dendritic cell maturation under normoxic conditions. PLoS One 2010;5:e0010983
51. Peyssonnaux C, Datta V, Cramer T, et al. Hif-1alpha expression regulates the bactericidal capacity of phagocytes. J Clin Invest 2005;115:1806-15 (Pubitemid 40979719)
52. Cramer T, Yamanishi Y, Clausen BE, et al. Hif-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003;112:645-57 (Pubitemid 36331777)
53. Nizet V, Johnson RS. Interdependence of hypoxic and innate immune responses. Nat Rev Immunol 2009;9:609-17
54. Walmsley SR, Print C, Farahi N, et al. Hypoxia-induced neutrophil survival is mediated by hif-1alpha-dependent nfkappab activity. J Exp Med 2005;201:105-15 (Pubitemid 40130088)
55. Dang EV, Barbi J, Yang HY, et al. Control of t(h)17/t(reg) balance by hypoxia-inducible factor 1. Cell 2011;146:772-84
56. Yamashita T, Iwakura T, Matsui K, et al. Il-6-mediated th17 differentiation through rorgt is essential for the initiation of experimental autoimmune myocarditis. Cardiovasc Res 2011;91:640-8
57. Yuan J, Cao AL, Yu M, et al. Th17 cells facilitate the humoral immune response in patients with acute viral myocarditis. J Clin Immunol 2010;30:226-34
58. Daniels MD, Hyland KV, Wang K, et al. Recombinant cardiac myosin fragment induces experimental autoimmune myocarditis via activation of th1 and th17 immunity. Autoimmunity 2008;41:490-9
59. Takeda K, Ichiki T, Narabayashi E, et al. Inhibition of prolyl hydroxylase domaincontaining protein suppressed lipopolysaccharide-induced tnf-alpha expression. Arterioscler Thromb Vasc Biol 2009;29:2132-7
60. Ikeda J, Ichiki T, Matsuura H, et al. Deletion of phd2 in myeloid lineage attenuates hypertensive cardiovascular remodeling. J Am Heart Assoc 2013;2:e000178
61. Kapitsinou PP, Jaffe J, Michael M, et al. Preischemic targeting of hif prolyl hydroxylation inhibits fibrosis associated with acute kidney injury. Am J Physiol Renal Physiol 2012;302:F1172-9
62. Yu X, Fang Y, Ding X, et al. Transient hypoxia-inducible factor activation in rat renal ablation and reduced fibrosis with l-mimosine. Nephrology (Carlton) 2012;17:58-67
63. Rosenberger P, Schwab JM, Mirakaj V, et al. Hypoxia-inducible factordependent induction of netrin-1 dampens inflammation caused by hypoxia. Nat Immunol 2009;10:195-202
64. Robinson A, Keely S, Karhausen J, et al. Mucosal protection by hypoxiainducible factor prolyl hydroxylase inhibition. Gastroenterology 2008;134:145-55 (Pubitemid 350309309)
65. Cummins EP, Seeballuck F, Keely SJ, et al. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 2008;134:156-65
66. Matsuura H, Ichiki T, Ikeda J, et al. Inhibition of prolyl hydroxylase domain-containing protein downregulates vascular angiotensin ii type 1 receptor. Hypertension 2011;58:386-93
67. Nwogu JI, Geenen D, Bean M, et al. Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation 2001;104:2216-21 (Pubitemid 33043303)